Last reviewed · How we verify
concurrent chemotherapy with radiation
concurrent chemotherapy with radiation is a Small molecule drug developed by Zhejiang Cancer Hospital. It is currently in Phase 3 development for Various types of cancer, including but not limited to breast cancer, lung cancer, and colorectal cancer.
Concurrent chemotherapy with radiation involves administering chemotherapy and radiation therapy simultaneously to treat cancer.
Concurrent chemotherapy with radiation is being studied in clinical trials for various conditions, including Human Papillomavirus-Related Carcinoma, Oropharyngeal Cancer, and Small Cell Lung Cancer. The treatment involves combining radiation therapy with small molecule chemotherapy agents, such as Anlotinib, and monoclonal antibodies, such as Durvalumab.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | concurrent chemotherapy with radiation |
|---|---|
| Sponsor | Zhejiang Cancer Hospital |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach aims to enhance the effectiveness of both treatments by exploiting the synergistic effects of chemotherapy and radiation on cancer cells. Chemotherapy can make cancer cells more sensitive to radiation, while radiation can increase the delivery of chemotherapy to the tumor site.
Approved indications
- Various types of cancer, including but not limited to breast cancer, lung cancer, and colorectal cancer
Common side effects
- Fatigue
- Nausea and vomiting
- Diarrhea
- Hair loss
- Skin rash
Key clinical trials
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer (PHASE1)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (PHASE3)
- Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma (PHASE2)
- A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
- Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- concurrent chemotherapy with radiation CI brief — competitive landscape report
- concurrent chemotherapy with radiation updates RSS · CI watch RSS
- Zhejiang Cancer Hospital portfolio CI
Frequently asked questions about concurrent chemotherapy with radiation
What is concurrent chemotherapy with radiation?
How does concurrent chemotherapy with radiation work?
What is concurrent chemotherapy with radiation used for?
Who makes concurrent chemotherapy with radiation?
What development phase is concurrent chemotherapy with radiation in?
What are the side effects of concurrent chemotherapy with radiation?
Related
- Manufacturer: Zhejiang Cancer Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Various types of cancer, including but not limited to breast cancer, lung cancer, and colorectal cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing